Live attenuated influenza vaccine: patient group direction (PGD) template
PGD template to support the administration of live attenuated influenza vaccine (Fluenz Trivalent®) in accordance with the national seasonal influenza vaccination programme.
- From:
- UK Health Security Agency
- Published
- 10 July 2024
- Last updated
- 1 July 2025 — See all updates
Applies to England
Documents
Influenza vaccine (Fluenz Trivalent®): patient group direction (PGD) template
Ref: UKHSA gateway number GOV-16524
MS Word Document, 4451.43 KBMB
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This PGD template supports the administration of live attenuated influenza vaccine (LAIV) (Fluenz Trivalent®) as part of the national seasonal influenza vaccination programme.
LAIV PGD version 14.0015.00 is valid from 1 September 20242025 to 1 April 2025.2026.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012).
This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.
Updates to this page
Published 10 July 2024
Last updated 1 July 2025
href="#full-history">+ show all updates
-
Added version 15, see page 4 for change history.
-
First published.
Sign up for emails or print this page
Details
This PGD template supports the administration of live attenuated influenza vaccine (LAIV) (Fluenz Trivalent®) as part of the national seasonal influenza vaccination programme.
LAIV PGD version 14.0015.00 is valid from 1 September 20242025 to 1 April 2025.2026.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012).
This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.
Updates to this page
-
Added version 15, see page 4 for change history.
-
First published.
Sign up for emails or print this page
Update history
2025-08-13 10:13
Added information about the addendum.
2025-08-08 09:30
Added ‘Addendum to: Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD)’
2025-07-01 12:00
Added version 15, see page 4 for change history.
2024-07-10 11:00
First published.